Muscle–Brain Crosstalk: Mechanisms, Clinical Relevance, and Emerging Therapeutic Perspectives

Abstract

Muscle–brain crosstalk represents a pivotal bidirectional communication pathway influencing both neuromuscular and central nervous system (CNS) health. Recent advances in molecular biology and neurophysiology have elucidated a complex network whereby skeletal muscle exerts endocrine-like effects on the CNS via the secretion of myokines, while the brain modulates muscle function through neural and humoral signaling. This article synthesizes current evidence on the epidemiology, pathophysiological mechanisms, risk factors, clinical features, diagnostic approaches, management strategies, and emerging therapies surrounding muscle–brain crosstalk, highlighting its significance in geriatric medicine, neurodegenerative diseases, and rehabilitation. The review further integrates guideline-based recommendations and explores potential avenues for future research and clinical application.

Introduction

The intricate relationship between skeletal muscle and the brain extends beyond simple neuromuscular control, encompassing a dynamic molecular dialogue that influences systemic health. This interplay, termed muscle–brain crosstalk, is increasingly recognized as a fundamental determinant in the aging process, cognitive function, and the pathogenesis of neuromuscular and neurodegenerative disorders. Understanding this bidirectional communication is essential for clinicians, as it underpins the rationale for integrated therapeutic strategies in conditions such as sarcopenia, dementia, and stroke rehabilitation. This review provides a comprehensive overview of the mechanisms, clinical implications, and translational potential of muscle–brain crosstalk, drawing upon the latest research and expert consensus.

Epidemiology / Disease Burden

The clinical impact of disrupted muscle–brain communication is profound, particularly among older adults. Sarcopenia affects up to 50% of individuals over 80, frequently coexisting with cognitive decline, frailty, and increased morbidity. Epidemiological data reveal a bidirectional association: reduced muscle mass and strength are linked to a higher risk of cognitive impairment, while neurodegenerative diseases often precipitate muscle atrophy and functional disability. The global burden of dementia and related disorders estimated at over 55 million cases worldwide underscores the need to address the neuromuscular axis in preventive and therapeutic strategies.

Pathophysiology

Muscle–brain crosstalk is mediated by a spectrum of signaling molecules, including myokines (e.g., irisin, brain-derived neurotrophic factor [BDNF]), cytokines, and metabolites released during muscle contraction. These factors cross the blood–brain barrier, modulating neurogenesis, synaptic plasticity, and neuroinflammation. Conversely, the CNS regulates muscle homeostasis via motor neuron signaling and neurotrophic support. Chronic inflammation, mitochondrial dysfunction, and hormonal dysregulation disrupt this communication, contributing to both muscle wasting and cognitive deficits. Notably, exercise-induced myokines such as irisin upregulate BDNF expression in the hippocampus, promoting neuroprotection and synaptic integrity.

Risk Factors

Age-related decline in physical activity, chronic inflammatory states, metabolic syndrome, and neurodegenerative diseases are key risk factors for impaired muscle–brain crosstalk. Genetics, nutritional deficiencies, and comorbidities such as diabetes and cardiovascular disease further exacerbate vulnerability. Sedentary lifestyle and sarcopenic obesity characterized by low muscle mass with increased adiposity have emerged as potent contributors to neuromuscular and cognitive decline.

Clinical Features

Patients presenting with disrupted muscle–brain communication may exhibit concurrent physical and cognitive symptoms: reduced muscle strength, fatigue, impaired balance, memory loss, executive dysfunction, and mood disturbances. In clinical practice, these manifestations frequently overlap in syndromes such as frailty, sarcopenia, mild cognitive impairment, and early dementia. Recognizing the constellation of neuromuscular and neurocognitive signs is crucial for early intervention.

Diagnosis

A comprehensive diagnostic approach integrates clinical assessment with objective measurements of muscle mass, strength (e.g., grip strength), and function (e.g., gait speed, chair stand test), alongside cognitive evaluation using tools such as the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA). Laboratory investigations may include inflammatory markers, hormonal profiles, and imaging (MRI, PET) to assess neurodegeneration and muscle quality. Emerging biomarkers, such as circulating myokines and neurotrophic factors, are under investigation for their potential diagnostic utility.

Treatment & Management

Management strategies focus on addressing both muscle and brain health through multimodal interventions. Resistance and aerobic exercise programs are the cornerstone, shown to enhance muscle mass, strength, and cognitive function via upregulation of myokines and neurotrophic factors. Nutritional optimization with adequate protein, vitamin D, and omega-3 fatty acids supports both neuromuscular and neurocognitive function. Pharmacological therapies targeting inflammation, anabolic hormones, and neurotrophic pathways are under development, though evidence remains limited. Multidisciplinary care, incorporating physical therapy, cognitive training, and psychosocial support, is recommended for optimal outcomes.

Recent Advances / Emerging Therapies

Recent research has identified novel myokines (e.g., cathepsin B, meteorin-like protein), exerkines, and microRNA-mediated pathways as key mediators of muscle–brain crosstalk. Experimental therapies include recombinant myokines, BDNF analogs, and small molecules modulating neuroinflammatory and metabolic pathways. Non-invasive neuromodulation techniques, such as transcranial magnetic stimulation (TMS) combined with exercise, are being explored to synergistically enhance neuroplasticity and motor recovery. The potential for personalized medicine utilizing genetic and biomarker profiling offers promise for tailoring interventions to individual risk profiles.

Guideline Recommendations

International guidelines emphasize the integration of physical activity, nutritional support, and cognitive engagement in the prevention and management of both sarcopenia and cognitive impairment. The European Working Group on Sarcopenia in Older People (EWGSOP) and the World Health Organization (WHO) recommend at least 150 minutes of moderate-intensity exercise weekly, resistance training, and regular cognitive assessment in at-risk populations. Early screening and intervention for neuromuscular and cognitive decline are advocated to mitigate progression and enhance quality of life.

Conclusion

Muscle–brain crosstalk is a critical determinant of physical and cognitive health across the lifespan, with profound implications for the prevention and management of age-related and neurodegenerative disorders. Advances in molecular research have expanded our understanding of the underlying mechanisms, offering new opportunities for therapeutic innovation. Clinicians should adopt an integrated, multidisciplinary approach emphasizing exercise, nutrition, and cognitive engagement to optimize neuromuscular and neurocognitive outcomes. Continued research is warranted to further delineate the molecular mediators and translate emerging therapies into clinical practice.